EGFR and cancer: We focused on drugs that were more effective at targeting core histone mutant cancer cells and found that these cells exhibited significantly higher sensitivities to several biologically relevant repurposed and/or cancer drugs, including multiple epithelial growth factor receptor (EGFR) inhibitors (e.g., neratinib, pelitinib, Fig. 9b, c) and other drugs targeting cell growth pathways, indicating a potential therapeutic strategy.